Compositions and methods to treat herpes simplex virus infections
First Claim
Patent Images
1. A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising a vector encoding:
- a Cas9 endonuclease; and
a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9 endonuclease to the region of HSV nucleic acid.
1 Assignment
0 Petitions
Accused Products
Abstract
Herpes simplex virus (HSV) including herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are a persistent cause of human disease with no known cure. Guided nuclease systems target specific regions of the HSV-1 and HSV-2 genomes, disrupting the virus'"'"' nucleic acid and rendering even latent viruses incapacitated.
-
Citations
21 Claims
-
1. A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising a vector encoding:
-
a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method for treating a herpes simplex virus (HSV) infection, the method comprising:
-
introducing into a cell of a host, (i) a vector encoding a Cas9 endonuclease and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, or (ii) a ribonucleoprotein that includes the Cas9 endonuclease and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, wherein the guide RNA is capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. - View Dependent Claims (8, 9, 10, 11, 12)
-
-
13. A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising a ribonucleoprotein, wherein the ribonucleoprotein comprises:
-
a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. - View Dependent Claims (14, 15, 16)
-
-
17. A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising:
-
an mRNA encoding a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9endonuclease to the region of HSV nucleic acid. - View Dependent Claims (18, 19, 20, 21)
-
Specification